EXACT Therapeutics AS Awarded NOK 7.4 M Grant for the Development of its Next Generation Ultrasound Transducer and Navigation System for ACT®

OSLO/ LONDON: 21 December 2021: EXACT Therapeutics AS (“EXACT-Tx” or “the Company”, Euronext Growth: EXTX), a clinical-stage precision health company developing the Acoustic Cluster Therapy (ACT®), a proprietary ultrasound-mediated drug delivery platform to enhance the efficacy of therapies across multiple diseases, today announces the award of a research and innovation grant from the Norwegian Research Council (NRC) of NOK 7.4 million for its research-based project “Ultrasound Transducer for Acoustic Cluster Therapy.”

The funding will support the Company’s work with its partner GE Healthcare for the development of a next-generation, bespoke, dual-frequency transducer (ultrasound probe) and a precision navigation system to help guide the ACT® procedure for targeted drug delivery in patients to allow real-time monitoring by medical professionals in the clinical setting.

Read more…